Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 321,324 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 321,324 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at approximately $54,687,391.44. The trade was a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT traded up $0.93 during midday trading on Wednesday, reaching $25.49. 2,145,752 shares of the company’s stock traded hands, compared to its average volume of 2,579,911. The company has a fifty day simple moving average of $21.75 and a two-hundred day simple moving average of $17.24. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16. The company has a market cap of $4.07 billion, a P/E ratio of -62.17 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.Adaptive Biotechnologies’s revenue was up 21.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) EPS. Equities analysts predict that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ADPT has been the subject of several research analyst reports. TD Cowen upped their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. dropped their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Morgan Stanley increased their price objective on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Finally, Guggenheim raised their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $24.42.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Allworth Financial LP acquired a new position in shares of Adaptive Biotechnologies during the 2nd quarter valued at about $35,000. Caitong International Asset Management Co. Ltd acquired a new stake in Adaptive Biotechnologies during the fourth quarter worth about $28,000. EverSource Wealth Advisors LLC increased its position in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the last quarter. Assetmark Inc. raised its stake in Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new position in Adaptive Biotechnologies during the fourth quarter worth about $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.